CD19 and diffuse large B-cell lymphoma: Two CD19-specific CAR T-cell products, namely Kymriah® (Novartis) and Yescarta® (Kite Pharma), have been recently approved by the US Regulatory Agency Food and Drug Administration and subsequently by the European Medicines Agency for treating B cell ALL and diffuse large B-cell lymphoma (DLBCL), respectively (86).